Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

详细信息查看全文

作者：Thomas K. Eigentler^a ; ¹ ; ^{thomas.eigentler@med.uni-tuebingen.de" class="auth_mail" title="E-mail the corresponding author} ; Jessica C. Hassel^b ; ¹ ; ^{jessica.hassel@med.uni-heidelberg.de" class="auth_mail" title="E-mail the corresponding author} ; Carola Berking^c ; ^{carola.berking@med.uni-muenchen.de" class="auth_mail" title="E-mail the corresponding author} ; Jens Aberle^d ; ^{aberle@uke.de" class="auth_mail" title="E-mail the corresponding author} ; Oliver Bachmann^e ; ^{bachmann.oliver@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author} ; Viktor Grü ; nwald^f ; ^{Gruenwald.Victor@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author} ; Katharina C. Kä ; hler^g ; ^{kckaehler@dermatology.uni-kiel.de" class="auth_mail" title="E-mail the corresponding author} ; Carmen Loquai^h ; ^{Carmen.Loquai@unimedizin-mainz.de" class="auth_mail" title="E-mail the corresponding author} ; Niels Reinmuthⁱ ; ^{n.reinmuth@lungenclinic.de" class="auth_mail" title="E-mail the corresponding author} ; Martin Steins^j ; ^{martin.steins@med.uni-heidelberg.de" class="auth_mail" title="E-mail the corresponding author} ; Lisa Zimmer^k ; ^{lisa.zimmer@uk-essen.de" class="auth_mail" title="E-mail the corresponding author} ; Anna Sendl^l ; ^{anna.sendl@bms.com" class="auth_mail" title="E-mail the corresponding author} ; Ralf Gutzmer^m ; ^{gutzmer.ralf@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author}
关键词：Immunotherapy ; PD-1 ; Nivolumab ; Pembrolizumab ; Adverse drug reaction ; Immune-related adverse events
刊名：Cancer Treatment Reviews
出版年：2016
出版时间：April 2016
年：2016
卷：45
期：Complete
页码：7-18
全文大小：669 K

文摘

class="label">•: Immune-mediated adverse drug reactions of grade 3–4 occur in up to 2% in the standard organ classes (according to MedDRA).
class="label">•: Early diagnosis and treatment is a key to manage immune-mediated adverse events.
class="label">•: Most immune-related adverse events are clinically well-manageable by use of systemic corticosteroids.
class="label">•: Anti-PD-1 therapy restart is indicated after recovery of events of mild or moderate severity.